Wall Street analysts expect that Humana Inc (NYSE:HUM) will report sales of $13.02 billion for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Humana’s earnings, with the lowest sales estimate coming in at $12.89 billion and the highest estimate coming in at $13.12 billion. Humana reported sales of $13.46 billion during the same quarter last year, which indicates a negative year over year growth rate of 3.3%. The firm is scheduled to issue its next earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that Humana will report full-year sales of $13.02 billion for the current fiscal year, with estimates ranging from $52.44 billion to $54.10 billion. For the next fiscal year, analysts anticipate that the business will report sales of $56.31 billion per share, with estimates ranging from $54.59 billion to $57.55 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Humana.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the prior year, the firm posted $3.18 earnings per share. The business’s quarterly revenue was down 3.0% compared to the same quarter last year.

HUM has been the subject of a number of recent research reports. BMO Capital Markets lifted their price objective on shares of Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. ValuEngine raised shares of Humana from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $242.00 price objective (down previously from $245.00) on shares of Humana in a research report on Thursday, November 9th. Credit Suisse Group cut their price objective on shares of Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Finally, Zacks Investment Research downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Twelve analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $256.30.

A number of hedge funds and other institutional investors have recently made changes to their positions in HUM. Janus Henderson Group PLC boosted its stake in Humana by 7,848.8% during the second quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock worth $377,192,000 after buying an additional 1,547,866 shares during the period. FMR LLC increased its stake in shares of Humana by 29.3% in the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after buying an additional 1,479,210 shares during the period. Koch Industries Inc. acquired a new stake in shares of Humana in the 2nd quarter valued at $404,000. TIAA CREF Investment Management LLC increased its stake in shares of Humana by 39.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,358,617 shares of the insurance provider’s stock valued at $326,910,000 after buying an additional 386,162 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of Humana by 39.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,322,413 shares of the insurance provider’s stock valued at $318,216,000 after buying an additional 376,177 shares during the period. Institutional investors and hedge funds own 94.19% of the company’s stock.

Shares of Humana (HUM) traded up $1.61 during trading hours on Wednesday, hitting $254.64. 898,800 shares of the company’s stock were exchanged, compared to its average volume of 1,377,120. Humana has a 1-year low of $186.25 and a 1-year high of $264.56. The stock has a market cap of $36,147.89, a PE ratio of 21.59, a P/E/G ratio of 1.74 and a beta of 0.88. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s payout ratio is 12.59%.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect Humana Inc (HUM) Will Announce Quarterly Sales of $13.02 Billion” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/zacks-analysts-expect-humana-inc-hum-will-announce-quarterly-sales-of-13-02-billion/1761891.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with Analyst Ratings Network's FREE daily email newsletter.